IP Library Granted Patent US 10,376,562
Granted Patent B2
US 10,376,562 · App. 14/775,386 · Granted Aug 13, 2019

Methods for promoting wound healing and hair growth comprising GDNF administration

Inventors: Robert E. Braun (Bar Harbor, ME); Manju Sharma (Bar Harbor, ME)
Assignee: The Jackson Laboratory
A61K38/185A61K8/64A61Q7/00C07K14/4756
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,562
App. No.
14/775,386
Granted
Aug 13, 2019
Kind
B2
Abstract

The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.

Claims (13)

1. A method for promoting hair growth on a subject, the method comprising the steps of: (a) administering at a site of desired hair growth on said subject a composition comprising a pharmaceutically effective dose of an isolated glial cell derived neurotrophic factor (GDNF), wherein said GDNF consists of residues 78-211 of SEQ ID NO:7 or residues 118-211 of SEQ ID NO:7; and (b) repeating said administrating step for a time period sufficient to promote said hair growth on said subject.

2. The method of claim 1 , wherein said GDNF consists of the amino acid sequence of residues 78-211 of SEQ ID NO:7.

3. The method of claim 2 , wherein said pharmaceutically effective dose is a dose sufficient to promote a 25% increase in hair follicle number or a 25% decrease in hair loss over a period of 3-4 months.

4. The method of claim 2 , wherein said administrating step is performed via topical contacting at said site of desired hair growth.

5. The method of claim 2 , wherein the GDNF is glycosylated at the glycosylation site occurring at amino acid residues 126-128 of SEQ ID NO:7 or at the glycosylation site occurring at amino acid residues 162-164 of SEQ ID NO:7.

6. The method of claim 2 , wherein said pharmaceutically effective dose consists of no more than about 10 mg/ml GDNF.

7. The method of claim 2 , wherein said repeating step is performed five times.

8. The method of claim 1 , wherein said GDNF consists of the amino acid sequence of residues 118-211 of SEQ ID NO:7.

9. The method of claim 8 , wherein said pharmaceutically effective dose is a dose sufficient to promote a 25% increase in hair follicle number or a 25% decrease in hair loss over a period of 3-4 months.

10. The method of claim 8 , wherein said administrating step is performed via topical contacting at said site of desired hair growth.

11. The method of claim 8 , wherein the GDNF is glycosylated at the glycosylation site occurring at amino acid residues 126-128 of SEQ ID NO:7 or at the glycosylation site occurring at amino acid residues 162-164 of SEQ ID NO:7.

12. The method of claim 8 , wherein said pharmaceutically effective dose consists of no more than about 10 mg/ml GDNF.

13. The method of claim 8 , wherein said repeating step is performed five times.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: BRAUN, ROBERT E.; SHARMA, MANJU
To: THE JACKSON LABORATORY
Reel/Frame 037199/0536 →
Continuity (2)
Provisional Application 61787870 · Mar 15, 2013
Related Publication 20160022773A1 · Jan 28, 2016
Cited By (1)
US 12,357,674